Press Releases

Newsroom
In the News
Press Releases
Resources for Journalists

Press Releases

Share
Share
and/or
516 News Releases found
New Study Examines the Longest-Running CAR T Cell Trial and Finds Acute Lymphoblastic Leukemia Patients May Do Better When Treated Early

Researchers at Memorial Sloan Kettering (MSK) report today in the New England Journal of Medicine that adult patients with acute lymphoblastic leukemia (ALL) who received chimeric antigen receptor (CAR) T cell therapy responded better if they had a small amount of disease at the time of the treatment. Compared with patients with a greater amount of disease, those in the low-disease category lived significantly longer and experienced fewer life-threatening side effects.  
Proof of Principle: Tri-Institutional Therapeutics Discovery Institute Drug Candidates “Graduate” to Next Phase of Development

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.
Viviane Tabar, MD, Chair of the Department of Neurosurgery, MSK
Viviane Tabar, MD, Named Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center

Viviane Tabar, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Tabar has been a vital faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology and the Vice Chair for Neurosurgical Research and Education.
MSK-IMPACT™ Is the First Tumor-Profiling Multiplex Panel Authorized by the FDA, Setting a New Pathway to Market for Future Oncopanels

The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a 468-gene oncopanel intended to detect gene mutations and other critical genetic aberrations in both rare and common cancers.
Gad Getz, Chuan He, and Aviv Regev
Young Investigators Named Winners of 2017 Paul Marks Prize for Cancer Research

Memorial Sloan Kettering (MSK) has named three investigators as recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes promising investigators aged 45 or younger at the time of nomination for their efforts in advancing cancer research.
Memorial Sloan Kettering Is Expanding Its Footprint in Long Island

Memorial Sloan Kettering, one of the nation’s top cancer treatment and research institutions, is expanding its reach on Long Island with a new 114,000-square-foot freestanding cancer treatment center in Nassau County. Once complete, MSK Nassau will house the area’s most comprehensive cancer care program, centrally located and staffed by the most forward-thinking and compassionate healthcare teams whose sole focus is caring for people with cancer.
Norwalk Hospital and Memorial Sloan Kettering Launch Unique Cancer Care Collaboration

Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital, a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital.
Cancer Immunologist Andrea Schietinger of Sloan Kettering Institute Honored with Prestigious NIH Director’s New Innovator Award

Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award. Dr. Schietinger was selected as a winner for her groundbreaking work in immune responses to cancer, molecular mechanisms underlying tumor-induced T cell dysfunction, and new approaches for cancer immunotherapy. A total of 55 New Innovator Awards were given out by the NIH this year.
Study Targets Gene-Guided Prevention and Treatment at the Time of Cancer Diagnosis

A new study from Kenneth Offit, MD, Chief of the Clinical Genetics Service and Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center (MSK), finds that more than half of inherited cancer gene mutations in people with advanced cancer are not detected using traditional methods based on family history.
Researchers Find Drug Combination Reduces Recurrence Risk in Patients with HER2-Positive Early Breast Cancer

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.